Interleukin 12-primed activated T cells as therapy for patients with metastatic melanoma (Phase I)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2009
At a glance
- Drugs Lymphokine-activated killer cells (Primary) ; Temozolomide
- Indications Malignant melanoma
- Focus Adverse reactions
- 23 Jul 2008 Planned patient number is now 18 as reported by ClinicalTrials.gov.
- 19 Jan 2007 Status changed from recruiting
- 25 Aug 2005 New trial record.